Vimarsana
Biggest News Aggregation in the World

Page 16 - Valuating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Valuating Today - Breaking & Trending Today

LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate - Vimarsana News

LinKinVax Welcomes Interim Results of the ANRS VRI06 Phase I Trial Evaluating a Novel HIV Vaccine Candidate

First vaccine to target dendritic cells, key activators of the immune system Novel delivery of the HIV envelope protein potentially critical to future vaccine strategies Safe and able

VALNEVA: Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 - Vimarsana News

VALNEVA: Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

New York & Saint-Herblain (France), February 17, 2023 - Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announce that Pfizer, as the study sponsor, has decided to discontinue

Newron Pharmaceuticals S.p.A.: Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia - Vimarsana News

Newron Pharmaceuticals S.p.A.: Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia

Highly compelling, statistically significant, clinically meaningful improvement in assessments of symptoms of psychosis, disease severity and global evaluation at one year;increase in magnitude of

Teck Resources evaluating options for steelmaking coal unit - Vimarsana News

Teck Resources evaluating options for steelmaking coal unit

Teck Resources Ltd on Thursday confirmed that it was evaluating options for its steelmaking coal business, including a possible spinoff.... | February 16, 2023

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma - Vimarsana News

Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

- Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus chemotherapy significantly prolongs survival in patients with advanced NPC - SHANGHAI, China